<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211938</url>
  </required_header>
  <id_info>
    <org_study_id>CSET 1542-JANORL2</org_study_id>
    <secondary_id>2009-017047-34</secondary_id>
    <nct_id>NCT01211938</nct_id>
  </id_info>
  <brief_title>Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract</brief_title>
  <acronym>JANORL2</acronym>
  <official_title>Randomized Phase 2 Trial Evaluating the Acute Toxicity of Two Protocols of Reirradiation After Surgery in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract - Single-fraction Radiotherapy With Concomitant 5FU and Hydrea Administered Every Other Week - Continuous Hyperfractionated Radiotherapy With Concomitant Cetuximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be randomised after surgery, provided surgery is macroscopically adequate, that&#xD;
      there is a flap of tissue protecting the vascular axis and that wound healing allows&#xD;
      reirradiation to begin less than 8 weeks after surgery.Reirradiation will begin in the two&#xD;
      arms less than 8 weeks after surgery in the irradiated area. The reirradiated volume : tumour&#xD;
      bed + a safety margin of &lt; 2 cm with immediate protection of bone marrow. This volume should&#xD;
      be jointly defined by the radiotherapist and the surgeon. During reirradiation, 60 Gy will be&#xD;
      delivered in the two arms but will last 11 weeks in the reference arm and 5 weeks in the&#xD;
      investigational arm.Acute toxicity (NCI-CTCAE) will be evaluated at the end of reirradiation&#xD;
      and at 6 months from randomization (first follow-up consultation)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2010</start_date>
  <completion_date type="Actual">February 25, 2017</completion_date>
  <primary_completion_date type="Actual">February 25, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity requiring an interruption of radiotherapy for more than 2 weeks</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival at 3 years and loco-regional control at 3 years</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>single-fraction radiotherapy with concomitant 5FU and Hydrea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>six 5-day cycles with a 9-day rest period between each cycle (split course). Each cycle includes : a single-fraction at a dose of 2 Gy per session for 5 sessions, combined with 5FU (800 mg/m2/day) and Hydrea (500 mg x 3/day) over the 5 days of the cycle. The total dose of radiotherapy is therefore 60 Gy delivered over 11 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hyperfractionated radiotherapy with concomitant Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bifractionated radiotherapy at a dose of 1.2 Gy per session at a rate of 2 sessions per day, at least 6h apart, 5 days per week over 5 weeks, without a split course, combined with Cetuximab. The total dose of radiotherapy is 60 Gy delivered over 5 weeks. Cetuximab (Erbitux√í) is to be administered in a 2-hour IV infusion at a dose of 400 mg/m2, 8 days before the start of radiotherapy, then in a 1-hour infusion at a dose of 250 mg/m2 on days 1, 8, 15, 22 and 29 of radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>single-fraction radiotherapy with concomitant 5FU and Hydrea</intervention_name>
    <description>single-fraction radiotherapy with concomitant 5FU and Hydrea</description>
    <arm_group_label>single-fraction radiotherapy with concomitant 5FU and Hydrea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hyperfractionated radiotherapy with concomitant Cetuximab</intervention_name>
    <description>hyperfractionated radiotherapy with concomitant Cetuximab</description>
    <arm_group_label>hyperfractionated radiotherapy with concomitant Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recurrent or second upper aerodigestive tract carcinoma in an area previously&#xD;
             irradiated at a dose of &gt;= 50 Gy&#xD;
&#xD;
          -  Squamous cell carcinoma&#xD;
&#xD;
          -  No grade III or IV sequels linked to the first radiation therapy (excepted radiation&#xD;
             sequels of salivary glands)&#xD;
&#xD;
          -  Relapse or second carcinoma (clinically invasive and/or lymph node recurrence &gt;= 3 cm&#xD;
             and/or the association of a local and lymph node recurrence&#xD;
&#xD;
          -  Oral cavity, pharynx, larynx (if rT4), cervical region (if &gt;3cm)&#xD;
&#xD;
          -  No distant metastases confirmed by chest CT scan, abdominal ultrasound (or CT scan) in&#xD;
             case of abnormal liver function, and bone scintigraphy in case of local symptoms&#xD;
&#xD;
          -  Surgery in the previously irradiated region allowing a macroscopically adequate&#xD;
             resection&#xD;
&#xD;
          -  Surgery and vascular protection with a myocutaneous or free flap&#xD;
&#xD;
          -  Interval &gt; = 6 months between the end of the first radiation treatment and surgery in&#xD;
             the previously irradiated area&#xD;
&#xD;
          -  Wound healing allowing reirradiation within an interval of 8 weeks after surgery in&#xD;
             the previouly irradiated area.&#xD;
&#xD;
          -  No participation in a clinical trial during the 30 days preceding inclusion&#xD;
&#xD;
          -  Age between 18 et 70 years.&#xD;
&#xD;
          -  Performance Status 0 or 1 according to WHO criteria.&#xD;
&#xD;
          -  Hematological function : neutrophils * 2 x 106/l, platelets : * 100 x 106/l,&#xD;
             hemoglobin : * 10 g/dl (or 6.2 mmol/l)&#xD;
&#xD;
          -  Liver function : total bilirubin (normal) ; ASAT (SGOT) and ALAT (SGPT) * 2.5 * upper&#xD;
             limit of normal (ULN) in each centre ; alkaline phosphatases * 5 * ULN. Patients whose&#xD;
             ASAT or ALAT levels &gt; 1.5 * ULN associated with alkaline phosphatases * 2.5 * ULN are&#xD;
             not eligible for the trial&#xD;
&#xD;
          -  Renal function : serum creatinine * 120 *mol/l (1.4 mg/dl) ; if creatinine level is &gt;&#xD;
             120 *mol/l, creatinine clearance should be * 60 ml/min.&#xD;
&#xD;
          -  Written consent of participants&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Superficial recurrence not associated with a lymph node relapse, isolated lymph node&#xD;
             recurrence measuring less than 3 cm&#xD;
&#xD;
          -  Distant metastases&#xD;
&#xD;
          -  Grade 3 or 4 sequels of first radiation therapy (excepted salivary gland sequels)&#xD;
&#xD;
          -  Macroscopically inadequate surgery&#xD;
&#xD;
          -  Delay in wound healing obliging reirradiation to be postponed beyond 8 weeks.&#xD;
&#xD;
          -  &gt; Grade 3 Toxicity induced by chemotherapy administered during a previous treatment&#xD;
&#xD;
          -  Hypersensitivity to Erbitux&#xD;
&#xD;
          -  Concomitant severe comorbidities (non exhaustive list)&#xD;
&#xD;
          -  Unstable cardiac comorbidity in spite of treatment.&#xD;
&#xD;
          -  Neurological or psychiatric history such as dementia, convulsions.&#xD;
&#xD;
          -  Severe uncontrolled infection&#xD;
&#xD;
          -  Obstructive bronchopneumopathy which required hospitalisation during the year&#xD;
             preceding inclusion.&#xD;
&#xD;
          -  Factors (psychological, familial, social or geographic) likely to hinder patient&#xD;
             compliance with the study protocol and follow-up are considered exclusion criteria.&#xD;
             These factors should be discussed with the patient before enrollment in the trial&#xD;
&#xD;
          -  Women who are pregnant, breast-feeding or of birthgiving age without effective&#xD;
             contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gustaveroussy.fr/fr/essai/cancers-orl-cancer-6</url>
    <description>ORL clinical trials on line in Institut Gustave Roussy</description>
  </link>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>September 29, 2010</study_first_submitted>
  <study_first_submitted_qc>September 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phase II/III</keyword>
  <keyword>upper aerodigestive tract carcinoma</keyword>
  <keyword>re irradiation</keyword>
  <keyword>Recurrent or second upper aerodigestive tract carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

